The latest trading session saw Recursion Pharmaceuticals (RXRX) ending at $7.25, denoting a +0.14% adjustment from its last day's close. The stock exceeded the S&P 500, which registered a loss of 0.76 ...

Ark Invest chief executive Cathie Wood says the most under-appreciated application of artificial intelligence is “healthcare” ...

SG Americas Securities LLC lowered its position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Free Report) by 44.8% during the fourth quarter, HoldingsChannel reports. The firm owned 49,343 shares ...

To get a sense of who is truly in control of Recursion Pharmaceuticals, Inc. ( NASDAQ:RXRX ), it is important to understand the ownership structure of the business. With 66% stake, institutions ...

Clear Creek Financial Management LLC lifted its stake in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Free Report) by 57.6% during the fourth quarter, according to its most recent 13F filing with ...

Bullish option flow detected in Recursion Pharmaceuticals (RXRX) with 16,974 calls trading, 1.0x expected, and implied vol increasing over 12 ...

In this article, we are going to take a look at where Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) stands against other cheap AI stocks to buy in 2025. Artificial Intelligence (AI) was a buzzword ...

Chief R&D and commercial officer Najat Khan, PhD, tells GEN Edge the company aims to improve design of studies, accelerate enrollment, and enhance evidence generation.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...